GSK rejects three Unilever bids to buy consumer healthcare arm, says unit was "fundamentally undervalued"
Sunday, January 16, 2022
United Kingdom-based pharmaceutical giant GlaxoSmithKline (GSK) confirmed January 15 it had rejected three "unsolicited, conditional and non-binding proposals" by Unilever to acquire its Consumer Healthcare division, including one bid of GBP50 billion in value made on December 20, believing Unilever "fundamentally undervalued" the business and its potential.
News that Unilever attempted to buy GSK Consumer Healthcare for 50 billion pounds, split between GBP41.7 billion in cash and 8.3 billion in Unilever shares, was first reported by The Sunday Times, and subsequently confirmed by both companies. Had the latest acquisition offer gone through, it would have been the largest deal since the beginning of the Covid-19 pandemic, and one of the biggest ever among companies listed on the London Stock Exchange.
A deal would likely mean integrating the GSK division into Unilever's own beauty and personal care business, which has seen profit margins struggle under Covid-19 lockdowns and higher costs for plastics and petrochemicals.
A brief response on the Unilever website confirmed it "had approached GSK and Pfizer about a potential acquisition", and adds GSK Consumer Healthcare "would be a strong strategic fit" as the company looks to rework its portfolio. GSK indicated the proposals were "carefully evaluated" by its board of directors, but unanimously rejected under the conclusion they "were not in the best interests of GSK shareholders" and "failed to reflect the intrinsic value of the business and its potential".
The Sunday Times have indicated the latest deal did not include an acquisition premium or recognition of corporate synergies; the joint venture between GSK and healthcare firm Pfizer, which holds a minority stake in the company, was initially projected to generate GBP500 million in cost savings by this year and realise "substantial cost synergies". The BBC's business editor Simon Jack wrote that a standard takeover premium would be about 30%, but could be reduced over the GBP10 billion in debt GSK was predicted to "leave on the books", of the GBP22 billion net debt GSK reported for Q3 2021.
The deals were assessed by the Board respective of a proposed demerger of GSK Consumer Health into a separate PLC in the middle of this year. Jack wrote GSK "always" had "an open mind to a trade sale to another party if the price was right." Unilever did not take into account the standard takeover premium, the value of cost savings and Board confidence Consumer Health could deliver "superior organic sales growth" of between four and six per cent in the medium term. This was despite valuations of about GBP50 billion by Goldman Sachs and Barclays analysts, and a lower GBP45 billion valuation by Jeffries Group.
There are no current talks between Unilever and either Pfizer or GSK, and the Unilever statement reads: "There can be no certainty that any agreement will be reached." Under CEO Alan Jope, Unilever has focused its investments and marketing on brands which "communicate a strong environmental or social purpose" by streamlining its holdings in items like beauty products and tea. Jope previously said Unilever would concentrate on smaller takeovers in industries like luxury beauty and wellness.
However, Russ Mould, investment director at AJ Bell, told the BBC this would be a "high risk deal" at a time investors are cautious about GSK's performance, but also a time of rising inflation he says encourages "consumer goods with loyal customers". Mould added despite strong cashflow, Unilever had recently missed targets on sales and profit margins, putting pressure on the CEO.
Pressure by activist shareholders Elliott Management Corporation and Bluebell Capital Partners have also mounted against GSK CEO Emma Walmsley over the unit's failure to develop a Covid-19 vaccine and Walmsley's own lack of scientific experience. GSK has been involved in the ongoing development of a Covid-19 vaccine with French biopharmaceutical company Sanofi, and announced preliminary results from Phase 3 trials last month.
In 2018, Unilever bought several consumer nutritional products from GSK, including its flagship product Horlicks, and merged its Indian subsidiary, Hindustan Unilever, with GSK Consumer Healthcare India.
- "Marmite-owner Unilever makes three bids for GSK consumer goods arm" — BBC News, January 15, 2022
- Siddharth Cavale, Ludwig Burger, Mrinmay Dey. "GSK rejects 50-billion-pound Unilever offer for consumer assets" — Reuters, January 15, 2022
- "Update - GSK Consumer Healthcare" — GlaxoSmithKline, January 15, 2022
- "Unilever statement in response to press reporting" — Unilever, January 14, 2022
- "Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation" — Sanofi, December 15, 2021
- Deloitte. "Third quarter 2021" — GlaxoSmithKline, October 27, 2021
- "GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture" — GlaxoSmithKline, December 19, 2018
- "Unilever to acquire Horlicks and other consumer healthcare nutrition products from GSK" — Unilever, December 2, 2018